- |||||||||| alicaforsen oral (ISIS-2302) / Atlantic Healthcare, mongersen (GED-0301) / BMS
Clinical, Journal: Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate? (Pubmed Central) - Aug 31, 2022
We illustrate the recent data indicating that the various batches of mongersen, used during the phase III program, are chemically different, with some of them being unable to downregulate Smad7 expression. Overall, these findings suggest the necessity of new clinical studies to further evaluate the efficacy of chemically homogenous batches of mongersen in patients with inflammatory bowel diseases (IBDs), and, at the same time, they can help understand the failure of other clinical trials with antisense oligonucleotides in IBD (i.e. alicaforsen).
- |||||||||| Entyvio (vedolizumab) / Takeda
Review, Journal: Interfering with leukocyte trafficking in Crohn's disease. (Pubmed Central) - Nov 14, 2019
Oral and subcutaneous therapies are in development. The safety, efficacy and practice points of licensed drugs are discussed, in addition to initial results from therapeutic trials.
|
